Source: Annual Congress 2006 - COPD – inflammation/miscellaneous
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
G. Balci, S. Dereli, L. Usta, E. Tellioglu, Y. Vatansever, R. Ozacar (Izmir, Turkey). The cost analysis of our COPD patients. Eur Respir J 2006; 28: Suppl. 50, 334

Member's Comments

No comment yet.

Related content which might interest you: Frequency of exacerbations in patients with COPD: an analysis of the SPIROMICS cohort Source: International Congress 2017 – COPD: latest insights into the management of patients Year: 2017 Direct cost analysis of COPD patients: A 1 year follow-up study Source: International Congress 2016 – Novel avenues in the treatment of COPD II Year: 2016 Hospitalization cost analysis due to acute COPD exacerbations Source: International Congress 2016 – How the increasing complexity of chronic care management challenges ethics and costs in our healthcare system Year: 2016 COPD in the time of COVID-19: an analysis of acute exacerbations and reported behavioural changes in patients with COPD Source: ERJ Open Res, 7 (1) 00718-2020; 10.1183/23120541.00718-2020 Year: 2021 A global survey conducted to determine frequency of exacerbations in COPD patients Source: Annual Congress 2013 –COPD treatment Year: 2013 Care-continuity for COPD patients Source: Annual Congress 2012 - Nursing led education and follow-up strategies: impact on readmission, self care and patient experiences Year: 2012 COPD patients Source: Eur Respir Monogr 2021; 90: 154-164 Year: 2021 A retrospective cohort study demonstrating the impact of an OPEP device on exacerbations in COPD patients with chronic bronchitis Source: International Congress 2016 – Hospitalisation and comorbidities in chronic lung diseases Year: 2016 Efficiency of different approaches for the assessment of the risk of exacerbations in patients with COPD Source: International Congress 2019 – Airway disease-associated exacerbations Year: 2019 Assessing the burden of repeated exacerbations among COPD patients Source: Eur Respir J 2004; 24: Suppl. 48, 64s Year: 2004 The complexities of patients with COPD Source: International Congress 2014 – Ceremony for the ERS Best Publication Maurizio Vignola Award for Innovation in Pneumology 2014 - Clinical Year in Review II Year: 2014 Is treatment with ICS and LABA cost-effective for COPD? Multinational economic analysis of the TORCH study Source: Eur Respir J 2010; 35: 532-539 Year: 2010 The cost of COPD: results from the SIRIBO study Source: Eur Respir J 2002; 20: Suppl. 38, 125s Year: 2002 COPD in elderly patients – an analysis of the DACCORD observational study Source: International Congress 2018 – COPD around the world Year: 2018 β-blockers and risk of COPD exacerbation requiring hospitalisation in patients with COPD Source: Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD Year: 2011 Health care costs in COPD patients with severe respiratory failure: a prospective analysis Source: Annual Congress 2009 - Organisation of care for individuals with chronic respiratory disease Year: 2009 The impact of comorbidities on the short-term serious health outcomes in hospitalized COPD patients due to exacerbation Source: Annual Congress 2013 –COPD treatment and others Year: 2013 The costs of exacerbations in COPD Source: Eur Respir J 2001; 18: Suppl. 33, 273s Year: 2001 Real life assessment of inhaler use and acute exacerbations in 2935 COPD patients Source: International Congress 2016 – Novel avenues in the treatment of COPD II Year: 2016